Maura Caufield1, Wynnis L Tom. 1. Georgetown University School of Medicine, Washington, District of Columbia, USA.
Abstract
BACKGROUND: Azathioprine is prescribed as a corticosteroid-sparing agent for many inflammatory conditions, including refractory atopic dermatitis (AD). There are limited prospective data on its appropriate use and monitoring for children with AD. OBJECTIVES: This study was designed to assess clinical response to azathioprine, determine the necessity for repeated measurement of thiopurine methyltransferase (TPMT) activity during treatment, and test the utility of measuring levels of the metabolites 6-thioguanine nucleotide and 6-methylmercaptopurine. METHODS: Twelve children with severe, recalcitrant AD were treated with oral azathioprine and followed prospectively. Disease severity was determined by the SCORing AD index. Baseline TPMT activity was measured and this was repeated along with 6-thioguanine nucleotide and 6-methylmercaptopurine measurement at times of stable improvement, inadequate response, or change in response. RESULTS: Azathioprine therapy was associated with clinical improvement in all but 1 patient. There were few adverse effects. Three patients showed a significant change in TPMT activity during treatment: 2 had a mild decrease and 1 demonstrated enzyme inducibility with an increase from the intermediate to the normal activity range. These changes, but not 6-thioguanine nucleotide or 6-methylmercaptopurine levels, inversely correlated with the clinical response to therapy. LIMITATIONS: Small sample size is a limitation. CONCLUSIONS: Azathioprine can be of benefit in the treatment of recalcitrant pediatric AD. Repeat assessment of TPMT activity may be helpful for evaluation of nonresponse or change in response and warrants further study. In contrast, measurement of thiopurine metabolites during treatment was not clinically useful.
BACKGROUND:Azathioprine is prescribed as a corticosteroid-sparing agent for many inflammatory conditions, including refractory atopic dermatitis (AD). There are limited prospective data on its appropriate use and monitoring for children with AD. OBJECTIVES: This study was designed to assess clinical response to azathioprine, determine the necessity for repeated measurement of thiopurine methyltransferase (TPMT) activity during treatment, and test the utility of measuring levels of the metabolites 6-thioguanine nucleotide and 6-methylmercaptopurine. METHODS: Twelve children with severe, recalcitrant AD were treated with oral azathioprine and followed prospectively. Disease severity was determined by the SCORing AD index. Baseline TPMT activity was measured and this was repeated along with 6-thioguanine nucleotide and 6-methylmercaptopurine measurement at times of stable improvement, inadequate response, or change in response. RESULTS:Azathioprine therapy was associated with clinical improvement in all but 1 patient. There were few adverse effects. Three patients showed a significant change in TPMT activity during treatment: 2 had a mild decrease and 1 demonstrated enzyme inducibility with an increase from the intermediate to the normal activity range. These changes, but not 6-thioguanine nucleotide or 6-methylmercaptopurine levels, inversely correlated with the clinical response to therapy. LIMITATIONS: Small sample size is a limitation. CONCLUSIONS:Azathioprine can be of benefit in the treatment of recalcitrant pediatric AD. Repeat assessment of TPMT activity may be helpful for evaluation of nonresponse or change in response and warrants further study. In contrast, measurement of thiopurine metabolites during treatment was not clinically useful.
Authors: M Lindqvist; U Hindorf; S Almer; P Söderkvist; M Ström; H Hjortswang; C Peterson Journal: Nucleosides Nucleotides Nucleic Acids Date: 2006 Impact factor: 1.381
Authors: M C Dubinsky; S Lamothe; H Y Yang; S R Targan; D Sinnett; Y Théorêt; E G Seidman Journal: Gastroenterology Date: 2000-04 Impact factor: 22.682
Authors: Karin Dilger; Elke Schaeffeler; Milan Lukas; Ulrike Strauch; Hans Herfarth; Ralph Müller; Matthias Schwab Journal: Ther Drug Monit Date: 2007-02 Impact factor: 3.681
Authors: J Berth-Jones; A Takwale; E Tan; G Barclay; S Agarwal; I Ahmed; K Hotchkiss; R A C Graham-Brown Journal: Br J Dermatol Date: 2002-08 Impact factor: 9.302
Authors: Nicholas R Fuggle; Walter Bragoli; Anjali Mahto; Mary Glover; Anna E Martinez; Veronica A Kinsler Journal: J Am Acad Dermatol Date: 2014-11-04 Impact factor: 11.527
Authors: Jung Eun Kim; Hyun Jeong Kim; Bark-Lynn Lew; Kyung Ho Lee; Seung Phil Hong; Yong Hyun Jang; Kui Young Park; Seong Jun Seo; Jung Min Bae; Eung Ho Choi; Ki Beom Suhr; Seung Chul Lee; Hyun Chang Ko; Young Lip Park; Sang Wook Son; Young Jun Seo; Yang Won Lee; Sang Hyun Cho; Chun Wook Park; Joo Young Roh Journal: Ann Dermatol Date: 2015-10-02 Impact factor: 1.444
Authors: Robert Sidbury; Dawn M Davis; David E Cohen; Kelly M Cordoro; Timothy G Berger; James N Bergman; Sarah L Chamlin; Kevin D Cooper; Steven R Feldman; Jon M Hanifin; Alfons Krol; David J Margolis; Amy S Paller; Kathryn Schwarzenberger; Robert A Silverman; Eric L Simpson; Wynnis L Tom; Hywel C Williams; Craig A Elmets; Julie Block; Christopher G Harrod; Wendy Smith Begolka; Lawrence F Eichenfield Journal: J Am Acad Dermatol Date: 2014-05-09 Impact factor: 11.527